Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 6.12%
As of Wednesday, August 19, AbCellera Biologics Inc.’s ABCL share price has surged by 6.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. ABCL
$12.01
0.89
8.00%
August 19, 2026 4:00:00 PM
EST
Volume: 10,743,924
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Commentary & Analysis
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 7.07%
As of Tuesday, August 11, AbCellera Biologics Inc.’s ABCL share price has surged by 7.07%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 33.84%
As of Monday, August 10, AbCellera Biologics Inc.’s ABCL share price has surged by 33.84%, which has investors questioning if this is right time to sell.Jenna Brashear
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 39.61%
As of Monday, August 10, AbCellera Biologics Inc.’s ABCL share price has surged by 39.61%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Is AbCellera Biologics Inc. (ABCL) Overvalued?
We dive into why AbCellera Biologics Inc. (ABCL) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,749.2 | $3,076.5 | 62% |
|
| Shares Out (Mil) | 305.6 | 96.5 | 83% |
|
| Institutional Ownership | 57.3% | 90.0% | 38% |
|
| Float (Mil) | 221.0 | 71.5 | 76% |
|
| Beta | 1.19 | 1.22 | 71% |
|
| Avg Daily Volume (000s) | 15,161 | 710 | 98% |
|
| Price Change (52-week) |
169.6% | 89.4% | 96% |
|
| Growth | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (20.3%) | 7.8% | 2% |
|
| Net Income (5yr) | (26.4%) | (13.7%) | 16% |
|
| EPS (5yr) | (25.3%) | 0.7% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.0%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 5 | 4 | |
| Current EPS | ($0.173) | ($0.656) | ($0.715) | |
| Month Ago EPS | ($0.175) | ($0.627) | ($0.705) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.177) | ($0.654) | ($0.720) | |
| Year/Year Chg | (4.4%) | 33.9% | 74.1% | |
| Financials | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $66 | $800 | 23% |
|
| Net Income (TTM) (Mil) | ($165) | ($31) | 8% |
|
| EPS (TTM) | ($0.546) | ($0.300) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($95) | $47 | 6% |
|
| Net Cash Flow (TTM) (Mil) | $27 | $5 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $130 | $270 | 46% |
|
| Enterprise Value (Q1) (Mil) | $2,459 | $3,795 | 52% |
|
| Valuation | ABCL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.96 | 3.68 | 72% |
|
| P/E | na | 39.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.5 | na |
|
| Ratios | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (198.9%) | 47.7% | 1% |
|
| Net Margin | (248.8%) | (3.2%) | 4% |
|
| ROA | (12.2%) | (4.3%) | 24% |
|
| ROE | (17.3%) | (7.9%) | 24% |
|
| Liabilities to Assets | 31.5% | 42.0% | 23% |
|
| F-Score | 5 | 5 | 50% |
|
AbCellera Biologics Inc. did not pass any screens on 8/20/2026.
